Back to Journals » Clinical Interventions in Aging » Volume 15

Circulating Glutamine and Alzheimer’s Disease: A Mendelian Randomization Study

Authors Adams CD

Received 20 November 2019

Accepted for publication 9 January 2020

Published 10 February 2020 Volume 2020:15 Pages 185—193

DOI https://doi.org/10.2147/CIA.S239350

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Richard Walker


Video abstract presented by Charleen D. Adams.

Views: 235

Charleen D Adams

Beckman Research Institute, Duarte, CA, USA

Correspondence: Charleen D Adams
Beckman Research Institute, City of Hope,1500 E. Duarte Road, Duarte, CA, USA
Tel +1 626-841-3931
Fax +1 626-841-9204
Email chaadams@coh.org

Background: Alzheimer’s disease is a devastating neurodegenerative disorder. Its worldwide prevalence is over 24 million and is expected to double by 2040. Finding ways to prevent its cognitive decline is urgent.
Methods: A two-sample Mendelian randomization study was performed instrumenting glutamine, which is abundant in blood, capable of crossing the blood-brain barrier, and involved in a metabolic cycle with glutamate in the brain.
Results: The results reveal a protective effect of circulating glutamine against Alzheimer’s disease (inverse-variance weighted method, odds ratio per 1-standard deviation increase in circulating glutamine = 0.83; 95% CI 0.71, 0.97; P = 0.02).
Conclusion: These findings lend credence to the emerging story supporting the modifiability of glutamine/glutamate metabolism for the prevention of cognitive decline. More circulating glutamine might mean that more substrate is available during times of stress, acting as a neuroprotectant. Modifications to exogenous glutamine may be worth exploring in future efforts to prevent and/or treat Alzheimer’s disease.

Keywords: Alzheimer’s disease, dementia, metabolism, glutamine, Mendelian randomization, prevention

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]